Amneal Sets $200m Sales Ambition For Biosimilar Trio
Looking To Expand Portfolio With Licensing Deals For Early-Entry Opportunities
• By David Wallace
Amneal has revealed a $200m “peak” sales estimate for its trio of biosimilars • Source: Shutterstock 
